OPKO Health, Inc.
$1.55B- Market cap
- $1.22B
- Debt
- +$687.93M
- Cash
- −$364.41M
Capital structure 64% equity / 36% debt · EV / Revenue 2.55x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: OPK stock price near parity vs AZTA $1.64 current versus $1.88 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AZTA's multiple
Implied fair value · at OPK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OPK FY 2025 (ended Dec 31, 2025) · AZTA FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 64% equity / 36% debt · EV / Revenue 2.55x
Capital structure 91% equity / 9% debt · EV / Revenue 2.07x
OPK carries the larger enterprise value at $1.55B against $1.23B; AZTA trades on the lower EV / Revenue multiple (2.07x vs 2.55x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OPKO Health, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
AZENTA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.54x
0.08x
Net debt / EBITDA
Leverage against operating earnings
-3.03x
4.70x
Cash and equivalents
Liquid reserves on the balance sheet
$364.41M
$279.78M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMARIN CORP PLC\UK
OPK vs AMRN
Sarepta Therapeutics, Inc.
OPK vs SRPT
Amphastar Pharmaceuticals, Inc.
OPK vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
OPK vs SUPN
Harmony Biosciences Holdings, Inc.
OPK vs HRMY
THERMO FISHER SCIENTIFIC INC.
OPK vs TMO
ILLUMINA, INC.
OPK vs ILMN
AGILENT TECHNOLOGIES, INC.
OPK vs A
BIO-TECHNE Corp
OPK vs TECH
BRUKER CORP
OPK vs BRKR
WATERS CORP /DE/
OPK vs WAT
$687.93M
$134.21M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.